Login / Signup

Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients.

Anna KuznetsovaAleksey LebedevKonstantin GromovElena KazennovaMaurizio ZazziFrancesca IncardonaAnders SönnerborgMarina Bobkova
Published in: Clinical case reports (2022)
General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre-existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first-line RPV-based ART regimens.
Keyphrases